Todd C. Davis
Chief Executive Officer at Ligand Pharmaceuticals Incorporated
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Ligand Pharmaceuticals Incorporated, 3 years.
Ligand Pharmaceuticals Incorporated
Director · Chief Executive Officer
Pelthos Therapeutics Inc.
Director
Palvella Therapeutics Inc.
Director
Chief executive roles
Ligand Pharmaceuticals Incorporated
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 8, 2024 | Ligand Pharmaceuticals Incorporated | Open-market purchase | +2,500 | $97.39 | $243,475 |
| Jun 28, 2024 | Ligand Pharmaceuticals Incorporated | Other | +350 | $60.71 | $21,249 |
| Mar 25, 2024 | Ligand Pharmaceuticals Incorporated | Option exercise | +7,448 | $46.20 | $344,098 |
| Mar 25, 2024 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,855 | $67.24 | $191,970 |
| Mar 25, 2024 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,156 | $68.51 | $147,708 |
| Mar 25, 2024 | Ligand Pharmaceuticals Incorporated | Option exercise | +3,556 | $66.19 | $235,372 |
| Feb 27, 2024 | Ligand Pharmaceuticals Incorporated | Grant or award | +32,436 | — | — |
| Feb 21, 2024 | Pelthos Therapeutics Inc. | Option exercise | +29,167 | $4.80 | $140,002 |
| Feb 15, 2024 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −1,381 | $74.65 | $103,092 |
| Sep 22, 2023 | Ligand Pharmaceuticals Incorporated | Open-market purchase | +4,000 | $59.38 | $237,520 |
| Jun 9, 2023 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −420 | $73.76 | $30,979 |
| Feb 23, 2023 | Ligand Pharmaceuticals Incorporated | Grant or award | +17,005 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.